Sermorelin 10mg/vial 1 Vial by Master Pharma

Usage

1. Confirm PCT timeline first.: Begin Sermorelin on the same day as your chosen SERM (e.g., Nolvadex or Clomid) so the GH axis is supported from the earliest stage of HPG recovery.
2. Reconstitute with sterile or bacteriostatic water.: Draw the chosen volume slowly into an insulin syringe, insert through the rubber stopper at an angle, and allow the liquid to run down the inner vial wall without directing a jet onto the lyophilised cake.
3. Swirl — never vortex.: Gentle rotation preserves peptide integrity; vigorous shaking degrades the 29-residue chain and reduces active yield.
4. Store the reconstituted vial at 2–8 °C.: Bacteriostatic water extends usable stability to approximately 20–28 days refrigerated; sterile water limits this to 72 hours — choose accordingly based on your protocol length.
5. Administer subcutaneously using an insulin syringe (28–31G).: Abdominal or thigh fat are suitable sites; vary the exact point each session to minimise local tissue irritation.
6. Log each dose against your PCT bloodwork schedule.: Because the primary goal is axis-neutral GH support, document IGF-1 and gonadotropin values at baseline and at the 4-week mark to confirm HPG recovery is proceeding independently.

Warnings

Frequently asked questions

Can you use Sermorelin during PCT without disrupting LH and FSH recovery?

Yes — Sermorelin is safe to use during PCT precisely because it does not interact with the hypothalamic-pituitary-gonadal axis. It binds the GHRH receptor on pituitary somatotrophs, a pathway entirely separate from gonadotropin regulation. LH and FSH recovery driven by SERM therapy proceeds unimpeded, meaning you gain GH-axis support without compromising the hormonal restoration PCT is designed to achieve.

Which peptides are suitable as an axis-neutral bridge after an androgenic cycle?

GHRH analogues like Sermorelin and GH secretagogues such as Ipamorelin are the most commonly used axis-neutral bridges because neither class signals through androgen or estrogen receptors. Sermorelin is particularly well characterised — its receptor pharmacology and short half-life are documented in peer-reviewed pharmacokinetic literature — making it a logical first-choice bridge for users who want GH support without suppressive liability during recovery.

How does Sermorelin help with joint pain during post-cycle therapy?

Post-cycle joint discomfort typically results from withdrawal of androgenic and estrogenic tissue support combined with AIs suppressing estrogen below physiological levels. Sermorelin mitigates this indirectly: elevated GH output upregulates IGF-1, which promotes collagen synthesis and supports synovial tissue health. This effect does not require androgen receptor activation, so joint support is provided without reintroducing suppressive compounds during the recovery window.

How many doses does Master Pharma's 10 mg Sermorelin vial provide for a PCT protocol?

At a standard PCT dose of 200 mcg per administration, a single 10 mg vial yields 50 individual doses. For a twice-daily protocol (400 mcg/day total), that equates to approximately 25 days of continuous use — enough to cover the active phase of most 4-week PCT protocols from a single vial. The 10 mg load is the highest available in this product group and reduces mid-protocol re-order risk.

What is the recommended refrigeration protocol once a Master Pharma Sermorelin vial has been reconstituted?

Reconstituted Sermorelin should be stored upright at 2–8 °C immediately after mixing and kept away from direct light. When bacteriostatic water is used for reconstitution, the solution remains stable for up to approximately 20–28 days under these conditions. Avoid freeze-thaw cycles, as repeated temperature shifts degrade peptide chain integrity and reduce active yield measured by HPLC. (2) angle_used

Manufacturer

The Sermorelin vial reviewed here sits within Master Pharma's lyophilised injectable peptide segment — the segment that demands the most stringent sterility and potency controls in the brand's portfolio, given the sensitivity of peptide chains to both endotoxin contamination and active-content drift during lyophilisation. For this SKU, analytical release operates on a lot-specific basis rather than a sampled or pooled model: HPLC active-content verification is performed against a reference standard matched specifically to Sermorelin's chromatographic behaviour, confirming that the 10 mg stated on the label reflects actual peptide mass in that production lot. LAL endotoxin quantification runs on the same lot — not a surrogate batch — so the Certificate of Analysis accompanying your vial documents the precise endotoxin control result for the units being shipped, not a historical average from a previous run.